Paracetamol seems to have similar success rates compared with indomethacin and ibuprofen in closing patent ductus arteriosus (PDA) in preterm infants, but with a better safety profile. The aim of our study was to evaluate the possible effects of paracetamol on cerebral oxygenation and cerebral blood flow velocity (CBFV). Infants with gestational age < 32 weeks with hemodynamically significant PDA (hsPDA) were prospectively studied by near infrared spectroscopy (NIRS) after the first dose of paracetamol (15 mg/kg) or ibuprofen (10 mg/kg). Cerebral regional oxygenation (rSO 2 C) and fractional oxygen extraction ratio (FOEC) were recorded 30 min before (T 0 ) and 60 ± 20 min (T 1 ), 180 ± 30 min (T 2 ), and 360 ± 30 min (T 3 ) after the beginning of drug infusion. Moreover, mean flow velocity (Vmean) and resistance index (RI = PSV-DV/PSV) measured with Doppler ultrasound in pericallosal artery were recorded at the same times. Significant changes in rSO 2 C and FOEC were not found during the study period within and between the groups. Similarly, Vmean did not vary in infants treated with paracetamol or ibuprofen, while RI decreased in the ibuprofen group.
Introduction
The patency of ductus arteriosus (PDA) is a frequent complication in preterm infants suffering from respiratory distress syndrome (RDS), and 60 to 70% of preterm infants of < 28-week gestation receive medical or surgical therapy for a PDA [4] . Neonates with a left-to-right shunt through the ductus complicating their RDS have higher respiratory failure, lower survival rate, and increased risk of intracranial hemorrhage (ICH), bronchopulmonary dysplasia (BPD), and necrotizing enterocolitis (NEC) [12] . Therefore, closure of PDA is indicated before a significant left-to-right shunting occurs. Patent ductus arteriosus can be treated effectively with the non-steroidal anti-inflammatory drug (NSAID) cyclooxygenase (COX) inhibitors indomethacin or ibuprofen, leading to permanent ductal closure in 70 to 80% of patients [11, 15] . However, indomethacin [11, 15] and ibuprofen [22, 30, 35] can induce severe gastrointestinal (i.e., isolated perforation, NEC) and renal (i.e., transient of permanent renal failure) adverse effects, due to their mesenteric and renal vasoconstrictive action, although ibuprofen has been found less harmful and is considered the first choice drug for PDA closure [22] .
The possible effects of these NSAIDs on infants' cerebral perfusion have been studied and if it is well known that indomethacin decreases cerebral blood flow (CBF) and oxygenation [3, 28] , the effect of ibuprofen is still debated because some studies exclude any effect [3, 21] while others report the same effect of indomethacin [3] .
These considerations suggest that the current pharmacological treatment of PDA in preterm infants is sub-optimal and explain why recent reports on the effectiveness of paracetamol in closing PDA has been welcomed with great interest by Neonatologists. The publication of either case series [5, 10, 23] or randomized controlled trials (RCTs) [8, 25] has been followed by the rapid diffusion of this treatment mainly in patients who have contraindications to indomethacin and ibuprofen or in whom these drugs have failed. In fact, paracetamol seems to have similar success rates to indomethacin and ibuprofen but with a better safety profile since previous studies did not report adverse effects following its administration [5, 8, 10, 23, 25] .
Considering that the paracetamol mechanism of action is not completely understood, but involves cyclooxygenase inhibition [32] , similarly to indomethacin and ibuprofen (although in a different way), we wondered if it might affect cerebral oxygenation and CBF.
Thus, we hypothesized that the treatment of hsPDA with paracetamol might affect cerebral perfusion and oxygenation in very preterm infants. The purpose of this study was to evaluate the possible effects of paracetamol on cerebral oxygenation with near infrared spectroscopy (NIRS) and on CBF velocity (CBFV) with Doppler ultrasound. Secondarily, we aimed to compare these effects to those of the first-choice drug ibuprofen.
Materials and methods
A prospective center-based study was carried out at the neonatal intensive care unit of Careggi University Hospital of Florence. The study was approved by the Tuscany pediatrics ethics committee. Infants with gestational age < 32 weeks were enrolled in the study, after parental informed consent, if they had an echocardiographic diagnosis of hemodynamically significant PDA (hsPDA) between 24 and 72 h of life, and RDS necessitating respiratory support. Exclusion criteria were major congenital anomalies; life-threatening infection or hydrops fetalis; persistent pulmonary hypertension (PPH); 3 and 4 grade intraventricular hemorrhage (IVH); need of cardiovascular support to avoid potential interference of catecholamine administration on CBF.
The diagnosis of hsPDA requiring treatment was made by echocardiographic demonstration of a ductal left-to-right shunt, with a left atrium to aortic root ratio > 1.3 or a ductal size > 1.5 mm [36] , and excluding the cases in which the closing flow pattern suggested a restrictive PDA. In studied patients, echocardiography was repeated after the first drug dose and at the end of treatment. All echocardiographic studies were performed by physicians who were unaware of the infants' treatment assignments.
Study design
Our patients were treated with ibuprofen (10 mg/kg i.v. followed by 5 mg/kg each, after 24 and 48 h; Pedea®, Orphan Europe, Paris, France) as first choice drug for hsPDA, while paracetamol (15 mg/kg i.v. every 6 h for 3 days; Paracetamolo Kabi®; Fresenius Kabi, Verona, Italy) was used in presence of contraindications to ibuprofen: urine output < 1 mL/kg/h during the preceding 12 h (with the exception of the first dose); a serum creatinine concentration > 1.5 mg/dL; platelet count < 50,000/mm 3 ; a tendency to bleed, as revealed by hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools, and oozing from puncture sites.
The medication was infused continuously over a period of 15 min.
Adverse events (urine output < 1 mL/kg/h, platelet count < 50,000/mm 3 , creatinine and AST increase > 20% in comparison with baseline values, isolated gastro-intestinal perforation and bleeding, 3-4 grade IVH, other bleedings) that occurred during or within 5 days after treatment were recorded.
NIRS measurements
Enrolled patients were studied continuously by NIRS (INVOS™ 5100, Covidien, Mansfield, MA, USA) for measurement of cerebral regional oxygenation (rSO 2 C) from 30 min before to 6 h after the first dose of drug infusion with a sampling interval of 6 s. A self-adhesive infant-neonatal sensor (OxyAlert™ NIRSensor, Covidien, Mansfield, MA, USA) containing a light-emitting diode and two distant sensors was fixed to the frontoparietal region of the infant's head for rSO 2 C recording. All measurements were taken with infants in supine position. During data recording, infants were mostly quiet or sleeping, and to reduce NIRS artifacts, the handling of patients during the study period was minimized. The rSO 2 measurements obtained with the NIRS technique reflect a combination of intravascular oxygenated/ deoxygenated venous, arterial, and capillary hemoglobin in a ratio of approximately 75:20:5 [37] .
Based on the measurements of rSO 2 C and SpO 2 , we calculated the cerebral fractional oxygen extraction ratio (FOEC) [9] , which is the difference between arterial SpO 2 measured by pulse oximetry and rSO 2 C measured by NIRS [FOEC = (SpO 2 -rSO 2 C)/SpO 2 ]. This parameter reflects the balance between oxygen delivery and oxygen consumption. Therefore, an increase in FOEC suggests an increase in the oxygen extraction by tissues, due to higher oxygen consumption in relation to oxygen delivery, while its decrease suggests less oxygen use in comparison to the supply [20] .
All NIRS data were recorded 30 min before (T 0 ) and 60 ± 20 min (T 1 ), 180 ± 30 min (T 2 ), and 360 ± 30 min (T 3 ) after the beginning of drug infusion.
Cerebral Doppler ultrasound measurements
Cerebral blood flow velocity was studied in the pericallosal artery using two-dimensional Doppler ultrasounds with a spectral analyzer (Philips ® Sonos 7500 Ultrasound, Andover. CT, USA). Five sequential cardiac cycles of optimal quality (maximal amplitude of the velocity curves) were recorded at each study time, maintaining the angle of insonation < 15°. Mean flow velocity (Vmean) and resistance index (RI = PSV-DV/PSV) [29] were recorded along with NIRS data.
Other collected data
Arterial pulse oximetry (SpO 2 ) and heart rate (IntelliVue MP40 Neonatal™, Philips, DA Best The Netherlands) were recorded continuously.
For each studied infant GA, birth weight, gender, type of delivery, antenatal steroids, venous umbilical blood pH, Apgar score at 5 min, highest FiO 2 , need of surfactant, noninvasive respiratory support [nasal continuous positive pressure (NCPAP), bilevel positive airway pressure (BiPAP), nasal intermittent ventilation (NIV)], and mechanical ventilation [patient-triggered ventilation (PTV), high frequency oscillatory ventilation (HFOV)], PDA closure, occurrence of sepsis, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), IVH, periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), length of stay in hospital, and mortality were recorded. BPD was defined as oxygen requirement at 36 weeks PMA [7] . NEC was defined as Bell's stage 2 or higher [2] . Sepsis was diagnosed when patients developed clinical signs and symptoms associated with a positive blood and/or liquor culture. IVH was diagnosed and staged accord-
Statistical analysis
The primary endpoint of our study was to evaluate possible changes in rSO 2 C in preterm infants treated with paracetamol for closing hsPDA. Thus, in planning our study, we calculated that a sample size of at least 10 infants was required to detect a statistically significant difference of 10% of rSO 2 C from a reference value of 65.0 ± 5.0, 30 min after the beginning of drug infusion (T 1 ) with 80% power at 0.05 level.
Clinical characteristics of the two groups were described by mean
For each NIRS variable (rSO 2 C, FOEC), we calculated the mean (±SD) from selected 5-min periods which were chosen at the end of T 0 , T 1 , T 2 , and T 3 . However, sometimes, this was not possible due to the occurrence of unwanted artifacts (generally infant movements): in this case, the 5-min period without artifacts closest to the end of T 0 , T 1 , T 2 , and T 3 was selected. Ultrasound data (Vmean, RI) were reported as means (±SDs).
Serial measurements of rSO 2 C, FOEC, Vmean, and RI in ibuprofen and paracetamol groups were compared by repeated-measure analysis of variance (ANOVA), while difference versus baseline (T 1 -T 0 , T 2 -T 0 , T 3 -T 0 ) was compared between the groups using the Student's "t" test for parametric data, as our data have a normal distribution.
Results
Eleven and ten infants were enrolled in the paracetamol and ibuprofen groups, respectively. Among infants in the paracetamol group, three had urine output < 1 mL/kg/h, three had a serum creatinine concentration > 1.5 mg/dL, two a platelet count < 50,000/mm 3 , and three a tendency to bleed. Patients' clinical characteristics were similar in the two groups (Table 1) . Infants' heart rate and SpO 2 did not significantly change during the study in either group (unreported data).
There were no significant changes in rSO 2 C and FOEC during the study period in either group (Table 2) . Similarly, Vmean did not vary in infants treated with paracetamol or ibuprofen, while RI decreased in the ibuprofen group (P < 0.01) ( Table 3) .
We observed that baseline values of rSO 2 C and FOEC tended to be lower in the paracetamol than in the ibuprofen group, but differences vs. baseline evaluated at T 1 (T 0 -T 1 ), T 2 (T 0 -T 2 ), and T 3 (T 0 -T 3 ) were similar suggesting that both drugs did not affect rSO 2 C and FOEC (Fig. 1) . Similarly, we found that differences vs. baseline values of Vmean and RI did ing to the classification of Papile et al [27] . PVL and ROP were diagnosed according to De Vries et al. [6] and International Classification of ROP [13] , respectively. not differ between infants in the paracetamol and ibuprofen groups (Fig. 1) .
PDA closure rate was similar in the paracetamol and ibuprofen group (Table 1) . One infant in the paracetamol group (grade 3 IVH) and one infant in the ibuprofen group (isolated intestinal perforation) experienced adverse events.
Discussion
This is the first study which investigates the effects of paracetamol on cerebral oxygenation in preterm infants with hsPDA. We observed that rSO 2 C did not change during the 6 h following its first administration and, as expected, also 
Hospital stay (day) 67 ± 52 65 ± 18 0.892 Table 2 Changes in rSO 2 C and FOEC at T 0 , T 1 , T 2 , and T 3 in paracetamol and ibuprofen group. Mean ± SD
Paracetamol group (n = 11) rSO 2 C (%) 66.2 ± 1.4 67.3 ± 5. FOEC, did not change. These results are consistent with the stability of CBV, confirmed by the lack of changes of CBFV, and support previous promising data on the paracetamol safety profile: a total of 74 preterm neonates with hsPDA have been treated with paracetamol (oral or intravenous) obtaining closure in 66 (89%) of them without the development of adverse effects [10, 14, 16, 19, 23, 24, 26, 33, 34, 38] . Moreover, two randomized single-center controlled studies compared the effectiveness and safety of oral paracetamol in comparison to ibuprofen for the treatment of PDA in preterm infants [5, 25] and found that the paracetamol PDA closure rate was similar to that of ibuprofen (81.2 vs. 78.8% [5] and 72.5 vs. 77.5% [25] , respectively) without adverse effects. On the other hand, paracetamol and traditional NSAIDs, such as ibuprofen or indomethacin, inhibit COX and reduce the levels of prostaglandins by different mechanisms: traditional NSAID's compete with the arachidonic acid substrate for the active site of cyclooxygenase (COX) subunit of Prostaglandin H Synthase (PGHS), while paracetamol also inhibits PGHS activity, but rather by acting on the peroxidase (POX) segment of the enzyme [17, 32] . In principle, although adverse effects of ibuprofen or indomethacin might be unrelated to PGHS inhibition, these differences in pharmacological mechanisms of action could contribute to explain the reported different safety profiles of these drugs, and mainly, for our purpose, the good safety profile of paracetamol in preterm infants that can include the maintaining of a stable cerebral perfusion and oxygenation.
We did not find differences in rSO 2 C and FOEC values between infants treated with paracetamol and infants treated with ibuprofen. Infants in the paracetamol group exhibited a trend toward lower rSO 2 C values in comparison with infants in the ibuprofen group. However, these values were in the normal range in agreement with Alderliesten et al. who recently reported that the normal range of rSO 2 C measured by NIRS in preterm infants is~65% during the first days of life, with neonatal sensors (as ours) measuring 10% higher than adult sensor [1] . Furthermore, difference versus baseline values of rSO 2 C and FOEC were similar between the groups, supporting the lack of a direct pharmacological effect of paracetamol and ibuprofen on cerebral perfusion and oxygenation in our population.
Cerebral ultrasound variables, namely Vmean and RI, did not differ between the two groups, but RI decreased significantly in the ibuprofen group. This can be attributed to the observed increase of diastolic velocity (DV) (although the increase was not statistically significant: unreported data) and was probably induced by the PDA closure, as previously reported [18, 31] , that was more frequent after the first drug dose in the ibuprofen than in the paracetamol group (70 vs. 27%). On the other hand, we speculate that this did not occur in the paracetamol group due to its different dose regimen and pharmacokinetics in comparison with ibuprofen, since the former is given at maintenance dose every 6 h and the latter is given daily starting with a loading dose. These differences can support the possibility that paracetamol acts on PDA more slowly than ibuprofen explaining the lack of RI changes that we observed in our study.
Limitation of our study was its observational design and different population in the paracetamol and ibuprofen groups, since ibuprofen is the first-choice drug for hsPDA pharmacological treatment and it is the unique licensed drug for PDA treatment in our country [22] . However, we believe that this point does not affect our results since the study population is homogeneous, as evidenced by similar clinical characteristics and outcome at discharge of infants in both groups, and the population size has been correctly calculated, although power calculation has been made only for rSO 2 C. Moreover, we did not investigate mesenteric and renal perfusion and oxygenation that could be affected by both hsPDA and its pharmacological treatment.
In conclusion, we found that the treatment of hsPDA with paracetamol does not affect cerebral perfusion and oxygenation in very preterm infants and this confirms its reported high safety profile. Moreover, we observed that cerebral oxygenation was similar in infants treated with paracetamol or ibuprofen, although in the ibuprofen group, the possible more rapid closure of PDA was associated to the decrease of RI. These data offer an original contribution to knowledge on the effects of the widening therapy with paracetamol for PDA closure in preterm infants.
